Prophylaxis in von Willebrand disease

Haemophilia

Volumn 14, Issue SUPPL. 5, 2008, Pages 47-53

  Berntorp, Erik ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Long term prophylaxis; Surgery; Von Willebrand disease; VWF FVIII concentrates

Indexed keywords

ANTIFIBRINOLYTIC AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 CONCENTRATE; DESMOPRESSIN; FANHDI; RISTOCETIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ARTICLE; BLEEDING; CLINICAL PROTOCOL; DISEASE CLASSIFICATION; DRUG DOSAGE FORM COMPARISON; DRUG POTENCY; DRUG RESPONSE; GENERAL SURGERY; HEMOPHILIA; HUMAN; INVASIVE PROCEDURE; LOADING DRUG DOSE; LONG TERM CARE; MONITORING; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROPHYLAXIS; SWEDEN; VON WILLEBRAND DISEASE;

COAGULANTS; DRUG ADMINISTRATION SCHEDULE; FACTOR VIII; HEMORRHAGE; HUMANS; PERIOPERATIVE CARE; VON WILLEBRAND DISEASE; VON WILLEBRAND FACTOR;

EID: 51349109299     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01851.x     Document Type: Article

References (31)

1. Berntorp E, Astermark J, Björkman S et al. Consensus perspectives on prophylactic therapy for haemophilia: Summary statement. Haemophilia 2003; 9 (Suppl. 1): 1-4.
2. Fischer K, Van Der Bom JG, Prejs R et al. Discontinuation of prophylactic therapy in severe haemophilia: Incidence and effects on outcome. Haemophilia 2001; 7: 544-50.
3. Federici AB, Mazurier C, Berntorp E et al. Biologic response to desmopressin in patients with severe type 1 and type 2 von Willebrand disease: Results of a multicenter European study. Blood 2004; 103: 2032-8.
4. Fressinaud E, Meyer D. International survey of patients with von Willebrand disease and angiodysplasia. Thromb Haemost 1993; 70: 546.
5. Morris ES, Hampton KK, Nesbitt IM, Preston FE, Thomas EG, Markris M. The management of von Willebrand's disease-associated gastrointestinal angiodysplasia. Blood Coagul Fibrinolysis 2001; 12: 143-8.
6. Rodeghiero F, Castaman G, Meyer D, Mannucci PM. Replacement therapy with virus-inactivated plasma concentrates in von Willebrand disease. Vox Sang 1992; 62: 193-9.
7. Mannucci PM, Tenconi PM, Castaman G, Rodeghiero F. Comparison of four virus-inactivated plasma concentrates for treatment of severe von Willebrand disease: A cross-over randomized trial. Blood 1992; 79: 3130-7.
8. Berntorp E, Nilsson IM. Use of a high-purity factor VIII concentrate (Hemate P) in von Willebrand's disease. Vox Sang 1989; 56: 212-7.
9. Lusher JM. Clinical guidelines for treating von Willebrand disease patients who are not candidates for DDAVP-a survey of European physicians. Haemophilia 1998; 4 (Suppl. 3): 11-4.
10. Goudemand J, Negrier C, Ounnoughene N, Sultan Y. Clinical management of patients with von Willebrand's disease with a VHP vWF concentrate: The French experience. Haemophilia 1998; 4 (Suppl. 3): 48-52.
11. Federici AB, Baudo F, Caracciolo C et al. Clinical efficacy of highly purified, doubly virus-inactivated factor VIII/von Willebrand factor concentrate (Fanhdi®) in the treatment of von Willebrand disease: A retrospective clinical study. Haemophilia 2002; 8: 761-7.
12. Foster PA. A perspective on the use of FVIII concentrates and cryoprecipitate prophylactically in surgery or therapeutically in severe bleeds in patients with von Willebrand disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 74: 1370-8.
13. Sadler JE, Mannucci PM, Berntorp E et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000; 84: 160-74.
14. Mannucci PM, Chediak J, Hanna W et al. Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: A prospective, multicenter study. Blood 2002; 99: 450-6.
15. Gill JC, Ewenstein BM, Thompson AR, Mueller-Velten G, Schwartz BA, Humate-P Study Group. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P®): Use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy. Haemophilia 2003; 9: 688-95.
16. Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA, Association of Hemophilia Clinic Directors of Canada. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate P/humate-P: Ristocetin cofactor unit dosing in patients with von Willebrand disease. Thromb Haemost 2002; 87: 224-30.
17. Pasi KJ, Collins PW, Keeling DM et.al. Management of von Willebrand disease: A guideline from the UK Haemophilia Centre Doctors' Organization. Haemophilia 2004; 10: 218-31.
18. Castillo R, Escolar G, Monteagudo J, Aznar-Salatti J, Reverter JC, Ordinas A. Hemostasis in patients with severe von Willebrand disease improves after normal platelet transfusion and normalizes with further correction of the plasma defect. Transfusion 1997; 37: 785-90.
19. Lethagen S, Carlson M, Hillarp A. A comparative in vitro evaluation of six von Willebrand factor concentrates. Haemophilia 2004; 10: 243-9.
20. Björkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet 2001; 40: 815-32.
21. Lethagen S, Kyrle PA, Castaman G, Haertel S, Mannucci PM, HAEMATE P Surgical Study Group. Von Willebrand factor/factor VIII concentrate (Haemate® P) dosing based on pharmacokinetics: A prospective multicenter trial in elective surgery. J Thromb Haemost 2007; 5: 1420-30.
22. Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest 1977; 60: 390-404.
23. Lubetsky A, Schulman S, Varon D et al. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease. Thromb Haemost 1999; 81: 229-33.
24. Smith MP, Rice KM, Bromidge ES et al. Continuous infusion therapy with very high purity von Willebrand factor concentrate in patients with severe von Willebrand disease. Blood Coagul Fibrinolysis 1997; 8: 6-12.
25. Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol 2000; 111: 1236-9.
26. Silwer J. Von Willebrand's disease in Sweden. Acta Paediatr Scand Suppl 1973; 238: 1-159.
27. Ramsay DM, Buist TA, Macleod DA, Heading RC. Persistent gastrointestinal bleeding due to angiodysplasia of the gut in von Willebrand's disease. Lancet 1976; 2: 275-8.
28. Berntorp E, Abshire T, vWD PN Steering Committee. The von Willebrand disease prophylaxis network (vWD PN): Exploring a treatment concept. Thromb Res 2006; 118 (Suppl. 1): S19-22.
29. Berntorp E, Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrinolysis 2005; 16 (Suppl. 1): S23-6.
30. Berntorp E. Prophylaxis and treatment of bleeding complications in von Willebrand disease type 3. Semin Thromb Hemost 2006; 32: 621-5.
31. Blanchette VS, Manco-Johnson M, Santagostino E, Ljung R. Optimizing factor prophylaxis for the haemophilia population: Where do we stand? Haemophilia 2004; 10 (Suppl. 4): 97-104.